SCHEMBL1685305

SCHEMBL1685305

Cc1cc(C=O)c(O)c(C(C)(C)c2ccccc2)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ERN1 O75460 7/20 0.53
ALDH1A1 P00352 3/20 0.40
ESR1 P03372 3/20 0.40
ESR2 Q92731 3/20 0.40
CYP3A4 P08684 1/20 0.40
CNR1 P21554 2/20 0.38
CNR2 P34972 2/20 0.38
CA2 P00918 1/20 0.38
POLB P06746 1/20 0.38
TYR P14679 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
NPSR1 Q6W5P4 1/20 0.36
SRC P12931 1/20 0.36
ALOX5 P09917 1/20 0.34
PTGS2 P35354 1/20 0.34
TSHR P16473 1/20 0.34
TRIM24 O15164 1/20 0.34
TRIM33 Q9UPN9 1/20 0.34
CYP2C19 P33261 1/20 0.34
HIF1A Q16665 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14859460 0.86 ERN1 (0.55) ERN1ALDH1A1CA2POLBTYR
SCHEMBL30829192 0.86 ERN1 (0.55) ERN1ALDH1A1CA2POLBTYR
SCHEMBL30829189 0.86 ESR1 (0.44) ERN1ALDH1A1ESR1ESR2CYP3A4
SCHEMBL3241119 0.86 ESR1 (0.44) ERN1ALDH1A1ESR1ESR2CYP3A4
SCHEMBL15771550 0.85 ALOX5 (0.48) ERN1ALDH1A1ESR1ESR2CYP3A4
SCHEMBL2197374 0.84 ERN1 (0.51) ERN1ALDH1A1ESR1ESR2CYP3A4
SCHEMBL13445622 0.82 MAPT (0.38) ERN1ALDH1A1ESR1ESR2CYP3A4
SCHEMBL14320100 0.81 ALOX5 (0.38) ERN1ALDH1A1ESR1ESR2CYP3A4
SCHEMBL6446758 0.81 ERN1 (0.45) ERN1ALDH1A1CYP3A4CA2TYR
SCHEMBL1685290 0.80 ERN1 (0.47) ERN1ALDH1A1ESR1ESR2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117430525-A Schiff base ligand and preparation method and application thereof 中化学科学技术研究有限公司 2024-01-23 CN disclosed
EP-2174928-B1 TRANSITION METAL COMPLEX COMPOUND, OLEFIN OLIGOMERIZATION CATALYST CONTAINING THE COMPOUND, AND METHOD FOR PRODUCING OLEFIN OLIGOMER PERFORMED IN THE PRESENCE OF THE CATALYST MITSUI CHEMICALS INC (JP) 2015-03-11 EP disclosed
US-8258361-B2 Transition metal complex compounds, olefin oligomerization catalysts including the compounds, and processes for producing olefin oligomers using the catalysts MITSUI CHEMICALS, INC. (JP) 2012-09-04 US disclosed
US-20110082325-A1 TRANSITION METAL COMPLEX COMPOUNDS, OLEFIN OLIGOMERIZATION CATALYSTS INCLUDING THE COMPOUNDS, AND PROCESSES FOR PRODUCING OLEFIN OLIGOMERS USING THE CATALYSTS MITSUI CHEMICALS, INC. 2011-04-07 US disclosed
EP-2178537-A1 BETA CARBOLINE DERIVATIVES AS ANTIDIABETIC COMPOUNDS Merck Sharp & Dohme Corp. (US) 2010-04-28 EP disclosed
EP-2174928-A1 TRANSITION METAL COMPLEX COMPOUND, OLEFIN POLYMERIZATION CATALYST CONTAINING THE COMPOUND, AND METHOD FOR PRODUCING OLEFIN POLYMER PERFORMED IN THE PRESENCE OF THE CATALYST Mitsui Chemicals, Inc. (JP) 2010-04-14 EP disclosed
US-7687579-B2 Ethylene (co) polymer and its use MITSUI CHEMICALS, INC. (JP) 2010-03-30 US disclosed
US-7563849-B2 Ethylene (co) polymer and its use MITSUI CHEMICALS, INC. (JP) 2009-07-21 US disclosed
WO-2009011836-A1 BETA CARBOLINE DERIVATIVES AS ANTIDIABETIC COMPOUNDS MERCK & CO., INC. (US) 2009-01-22 WO disclosed
US-7335716-B1 Ethylene (co)polymers and uses thereof MITSUI CHEMICALS, INC. (JP) 2008-02-26 US disclosed
US-20060047096-A1 Ethylene (co) polymer and its use TAKAHASHI MAMORU 2006-03-02 US disclosed
US-20060047079-A1 Ethylene (co) polymer and its use TAKAHASHI MAMORU 2006-03-02 US disclosed
US-6962890-B2 Olefin polymerization catalyst and process for olefin polymerization using the olefin polymerization catalyst MITSUI CHEMICALS, INC. (JP) 2005-11-08 US disclosed
EP-1582533-A1 Ethylene (co)polymer and its use MITSUI CHEMICALS, INC. (JP) 2005-10-05 EP disclosed
EP-1013674-B1 Olefin polymerization catalyst and process for olefin polymerization using this catalyst MITSUI CHEMICALS INC (JP) 2005-04-27 EP disclosed
US-20030027955-A1 Olefin polymerization catalyst, process for polymerizing olefins, ethylene polymer obtained by said process and use thereof MITSUI CHEMICALS, INC. (JP) 2003-02-06 US disclosed
EP-1270603-A2 Olefin polymerization catalyst, process for polymerizing olefins, ethylene polymer obtained by said process and use thereof Mitsui Chemicals, Inc. (JP) 2003-01-02 EP disclosed
US-20030004290-A1 Olefin polymerization catalyst and process for olefin polymerization using the olefin polymerization catalyst MITSUI CHEMICALS, INC. 2003-01-02 US disclosed
EP-1162211-A1 ETHYLENE (CO)POLYMERS AND USES THEREOF Mitsui Chemicals, Inc. (JP) 2001-12-12 EP disclosed
EP-1013674-A1 Olefin polymerization catalyst and process for olefin polymerization using this catalyst Mitsui Chemicals, Inc. (JP) 2000-06-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110082325-A1 TRANSITION METAL COMPLEX COMPOUNDS, OLEFIN OLIGOMERIZATION CATALYSTS INCLUDING THE COMPOUNDS, AND PROCESSES FOR PRODUCING OLEFIN OLIGOMERS USING THE CATALYSTS OSTC, COG4, COG7 ERN1 2069/4885ALDH1A1 2282/4885ESR1 1772/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.